Economics for everybody : Antiretroviral treatment and calculation of well-being by Shaun Da Costa

Learn more

• Bendavid E. & Bhattacharya J., 2009, “The President’s Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes” , Annals of Internal Medicine, 150 (10), pp. 688–695.
• Bor J., Herbst A. J., Newell M.-L. & Bärnighausen T., 2013, “Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment” , Science, 339 (6122), pp. 961–965.
• Da Costa S., O’Donnell O. & Van Gestel R., 2024, “Distributionally sensitive measurement and valuation of population health” , Journal of Health Economics, 93, 102847.
• Decancq K., Fleurbaey M. & Schokkaert E., 2017, “Wellbeing Inequality and Preference Heterogeneity” , Economica, 84(334), 210-238
• Fleurbaey M. & Gaulier G., 2009, “International comparisons of living standards by equivalent incomes” , Scandinavian Journal of Economics, 111 (3), 597–624.
• Forsythe S.S., McGreevey W., Whiteside A., Shah M., Cohen J., Hecht R., Bollinger L.A. & Kinghorn A., 2019, “Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic Benefits” , Health Affairs, 38 (7), 1163–1172.
• Tompsett A., 2020, “The Lazarus drug: the impact of antiretroviral therapy on economic growth” , Journal of Development Economics, 143, 102409.